JNJ Rybrevant Faspro Priority Review for HNSCC

Johnson & Johnson (JNJ) announced on July 30 that the FDA granted Priority Review to the supplemental Biologics License Application for subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after platinum chemotherapy and PD-1 or PD-L1 immunotherapy. Priority Review shortens the FDA timeline to approximately six months, putting the PDUFA in the first quarter of 2027.

The drug already received Breakthrough Therapy designation for this indication in February 2026. JNJ closed at $265.53 on July 29.

The OrigAMI-4 data

The sBLA is supported by the Phase 1b/2 OrigAMI-4 study (NCT06385080). In cohort 1, 102 patients received subcutaneous amivantamab monotherapy after prior platinum and checkpoint inhibitor treatment. The overall response rate was 42% (95% CI, 32% to 52%), with 15% achieving a complete response and a clinical benefit rate of 63%. At a median follow-up of 11.8 months, median progression-free survival was 6.8 months and median overall survival was 12.5 months.

The study excluded patients with HPV-positive oropharyngeal squamous cell carcinoma and those with prior anti-EGFR therapy, focusing on a heavily pretreated population with limited options.

Why the mechanism matters

Amivantamab is a bispecific antibody targeting both EGFR and MET, receptors overexpressed in 80 to 90% of HNSCC tumors and implicated in treatment resistance. It is the only therapy in HNSCC engineered to hit both targets simultaneously. The drug engages the immune system through its Fc domain, combining direct pathway inhibition with immune-mediated tumor killing.

RYBREVANT FASPRO was approved in December 2025 for EGFR-mutated non-small cell lung cancer, where it built adoption as a subcutaneous alternative to the IV formulation. Head and neck cancer is a different disease with different tumor biology, making this a genuine new indication rather than a label expansion.

The competitive picture

Post-platinum, post-IO head and neck cancer has a five-year survival rate of only 15%. Current options include Merck’s Keytruda (pembrolizumab) and Bristol Myers Squibb’s Erbitux (cetuximab), but neither targets MET and both have modest efficacy in this setting. The OrigAMI-4 data was presented at ASCO 2026 and published in the Journal of Clinical Oncology.

The risk: this is a single-arm Phase 1b/2 trial with ORR as the primary endpoint, not a randomized Phase 3 with overall survival. The FDA could require a confirmatory trial. For a primer on supplemental filings like this one, see our guide to sBLA and sNDA filings.

Source: JNJ press release | OrigAMI-4 on ClinicalTrials.gov

What It Means for the Trade

For JNJ at $265.53 and a mega-cap valuation, a head and neck sBLA is franchise plumbing, not a stock event. But the trade lens is about the rybrevant platform arc: amivantamab was an EGFR-mutant lung cancer asset, and this filing pushes the same bispecific into a biomarker-unselected solid tumor where EGFR and MET overexpression — present in 80 to 90% of HNSCC tumors — become the targets instead of specific mutations. If the FDA approves in Q1 2027, rybrevant becomes a multi-indication franchise with subcutaneous convenience built in, and the subcutaneous formulation is quietly the commercial story: office dosing without infusion-center time expands prescriber reach in community oncology.

The label pathway matters for expectations. This is an accelerated-style single-arm dataset supporting a sBLA in a post-platinum, post-IO population with a 15% five-year survival rate. The 42% ORR with 15% complete responses is genuinely striking for this setting — compare the modest single-digit response rates Keytruda and Erbitux deliver in the same line, though that is a cross-trial comparison, not head-to-head. The FDA rewarding it with Priority Review and February’s Breakthrough Therapy designation signals the agency sees the unmet need, but approval will likely come with a confirmatory-trial requirement attached.

Mechanism and Market Context

Amivantamab’s dual EGFR/MET targeting is the differentiated argument in HNSCC. These receptors drive both primary growth and resistance pathways in head and neck tumors, and no competing therapy hits both. The Fc-domain immune engagement adds antibody-mediated tumor killing on top of direct signaling blockade. The OrigAMI-4 cohort design is honest about its population: HPV-positive oropharyngeal patients excluded, prior anti-EGFR exposure excluded — a heavily pretreated, biologically unfavorable group where a 6.8-month median PFS and 12.5-month median OS represent a real improvement over historical expectations.

The exclusion of prior anti-EGFR patients also means the label, if granted, will likely avoid cetuximab-pretreated disease — carving the addressable population down but leaving Erbitux as a sequence partner rather than a competitor.

Risks and What Could Go Wrong

1. Single-arm evidentiary base. No placebo comparison disclosed for the OrigAMI-4 cohort — these are absolute response rates in an uncontrolled design. The FDA can approve with a commitment, or stall with a requirement for randomized data first; the latter adds years.
2. Response durability uncertainty. With median follow-up of only 11.8 months, the PFS and OS numbers are immature; later cuts could soften.
3. HPV-negative population performance. The trial excluded HPV-positive disease, and real-world HNSCC is heterogeneous — the label will be narrower than the headline indication sounds.
4. Franchise opportunity cost. JNJ’s oncology spend competes against its CAR-T and multiple myeloma programs; an HNSCC niche with confirmatory obligations ahead may draw modest commercial investment even after approval.

For JNJ holders this is a modest positive within a diversified story. For the amivantamab thesis, it is evidence the bispecific travels beyond lung — which is where the real option value sits.